Concepedia

Matt Hutmacher

MH

Statistics

Publications

10

Citations

419

H-Index

10

Active since

1991

Affiliations

Pfizer (United States)(Current)

Exelixis (United States)

Matt Hutmacher is an author at Pfizer (United States) specializing in pharmacology, medicine, and clinical pharmacology.

Publications per year

1991–2018

10

Publications

10

The pharmacokinetics of etanercept in patients with end-stage renal disease on haemodialysis

Burl R. Don, Gregory Spin, Aubri Rose et al. · Journal of Pharmacy and Pharmacology · 2005 · 79 citations · Full text

, , +17

Relationship between anger and pruritus perception in patients with chronic idiopathic urticaria and psoriasis

Rupert Conrad, Franziska Geiser, Gerhard Haidl et al. · Journal of the European Academy of Dermatology and Venereology · 2008 · 70 citations

, , +17

Exposure‐Response Analysis in Patients With Schizophrenia to Assess the Effect of Asenapine on QTc Prolongation

Sunny Chapel, Matt Hutmacher, George M. Haig et al. · The Journal of Clinical Pharmacology · 2009 · 62 citations

, , +17

Population exposure–response analysis of cabozantinib efficacy and safety endpoints in patients with renal cell carcinoma

Steven Lacy, Jace Nielsen, Bei Yang et al. · Cancer Chemotherapy and Pharmacology · 2018 · 51 citations · Full text

, , +17

A population pharmacokinetic model of cabozantinib in healthy volunteers and patients with various cancer types

Steven Lacy, Bei Yang, Jace Nielsen et al. · Cancer Chemotherapy and Pharmacology · 2018 · 34 citations · Full text

, , +15

1–5 of 10